- Home
- XAIR vs RNAZ Comparison
XAIR vs RNAZ Comparison
Compare XAIR & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XAIR | RNAZ |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 8.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | XAIR | RNAZ |
|---|---|---|
| Price | $1.21 | $10.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $11.00 | ★ $280.00 |
| AVG Volume (30 Days) | ★ 22.5M | 139.5K |
| Earning Date | 02-13-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,802,000.00 | N/A |
| Revenue This Year | $127.85 | N/A |
| Revenue Next Year | $179.78 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 147.74 | N/A |
| 52 Week Low | $0.67 | $6.08 |
| 52 Week High | $10.40 | $399.00 |
Technical Indicators
Market Signals| Indicator | XAIR | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 46.38 | 55.88 |
| Support Level | $1.43 | $8.35 |
| Resistance Level | $2.26 | $12.60 |
| Average True Range (ATR) | 0.33 | 0.96 |
| MACD | -0.04 | 0.22 |
| Stochastic Oscillator | 20.53 | 48.86 |
Price Performance
Historical ComparisonAbout XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.